Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
Hematology clinical trials are particularly complex, as they require both imaging and a comprehensive review of clinical data, leading to very quick deliverable timeline expectations. Perceptive’s operational strength and scientific knowledge meet the challenge head-on.
We have written over 185 hematology charters and have supported a range of indications including malignant and non-malignant conditions such as sickle cell disease. For hematologic malignancies, we have vast expertise across criteria, including:
Proven ability to deliver on tight timelines with uncompromised data quality
Success story: Delivered 1,200+ radiology and 1,500+ oncology reads for a multiple myeloma trial, achieving critical milestones on aggressive timelines. Breakthrough Therapy Designation granted and now FDA and EMA approved.
24/7 support for seamless communication and issue resolution
Close collaboration with sponsors and globally positioned teams keeps trials moving forward, with rapid escalations ensuring efficient and successful outcomes.
Expert protocol consultation
We design our approach to capture all essential imaging and clinical details from the start, supporting analysis, biomarkers, and efficacy endpoints with regulatory confidence.
Broad KOL network featuring renowned advisors and internal experts
Perceptive’s approach connects sponsors to a network of leading KOLs, including Bruce Cheson, MD, Shaji Kumar, MD, and Joseph Mikhael, MD, as well as our internal hematology experts.
Extensive experience in hematology trials with global regulatory approvals
Our team has supported over 360 malignant and non-malignant hematology trials, contributing to 59 regulatory approvals and 10 Breakthrough Therapy designations.
Meet Perceptive’s internal hematology experts, whose deep clinical and imaging expertise supports every phase of your hematology trial, from protocol design to regulatory success.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
"*" indicates required fields
Δ
